Stride Heads Into Earnings With Bears Dug In

LRN carries one of the heavier short positions in the mid-cap education space into its October 22 print, and the stock has been drifting lower all week.

Short interest is running at 18.3% of the free float, up about 5% over the past month, and the ORTEX short score has climbed to 67.2, its highest reading in the past two weeks, from 66.2 on October 12. That creeping accumulation is the clearest signal that bears are adding into the event rather than reducing exposure. The lending market, however, offers little comfort to those shorts: availability is ample at around 372%, meaning more than three shares are available to borrow for every one already lent out, and the cost to borrow has actually eased 14% over the past week to just 0.46%. Squeeze pressure is essentially absent. Options positioning is similarly unremarkable, with the put/call ratio at 0.72, barely above its 20-day average of 0.70 and well within the year's normal range.

The stock itself tells the story of a sharp recalibration. LRN is down nearly 5% on the week and flat over the past month, with Tuesday's session alone costing it 2.5%, closing at $78.95. That follows what was, earlier in the year, a 25% premarket spike after strong Q2 results. BMO Capital's Jeffrey Silber trimmed his target from $93 to $90 on October 5, keeping a Market Perform rating, the most recent analyst move on record. The broader consensus target stands at $107.50, implying meaningful upside from current levels, though bulls and bears are genuinely split on whether the stock can get there. The bull case rests on 7.5% revenue growth in Q2, rising enrollment and a $625 million cash-heavy balance sheet alongside an active buyback. Bears point to valuation: the stock already priced in a great deal of that optimism during its earlier rally, and at around 5x EV/EBITDA and a P/E near 10, the multiple appears modest in isolation but leaves little room for any guidance disappointment. Barrington Research and Canaccord hold the high end of the Street at $125, while Morgan Stanley's Equal-Weight at $95 and BMO's Market Perform at $90 anchor the cautious wing.

On the ownership side, Impactive Capital added over 190,000 shares in the quarter ending June, bringing its stake to just above 3%, and Dimensional Fund Advisors crossed the 5% reporting threshold in its most recent 13G, filed October 8. Neither is a Schedule 13D activist filing, and no activist is on the register. These are passive accumulations, but Dimensional's fresh filing does confirm ongoing institutional demand at current prices. The Vanguard Group, notably, disclosed it had reduced its stake to zero in its March 2026 13G/A, a shift worth tracking given the size of its prior position at 10.4%.

The print will test whether Stride's enrollment momentum and FY27 recovery thesis are tracking well enough to re-engage the buyers who sold into the summer rally, or whether the bears sitting on 18% of the float have correctly anticipated a more cautious outlook from management.